Springer Nature
Browse
12916_2019_1252_MOESM1_ESM.docx (13.81 kB)

Additional file 1: of Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening

Download (13.81 kB)
journal contribution
posted on 2019-01-31, 05:00 authored by Wei He, Louise Eriksson, Sven TĂśrnberg, Fredrik Strand, Per Hall, Kamila Czene
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant hormone therapy and breast cancer events derived from competing risk regression models. Discontinuation of adjuvant hormone therapy and breast cancer events in women diagnosed with breast cancer in Stockholm, Sweden, 2001–2008. (A) Screening non-participants vs participants; (B) screening non-participants vs participants diagnosed with screen-detected cancers; (C) screening non-participants vs participants diagnosed with interval cancers. Hazard ratio (HR) and 95% confidence intervals (95% CIs) were derived from competing risk regression models. (DOCX 13 kb)

Funding

Swedish Research Council

History